| Resveratrol and obesity: Can resveratrol relieve metabolic disturbances? M de Ligt, S Timmers, P Schrauwen Biochimica et biophysica acta (BBA)-molecular basis of disease 1852 (6 …, 2015 | 151 | 2015 |
| Resveratrol as add-on therapy in subjects with well-controlled type 2 diabetes: a randomized controlled trial S Timmers, M De Ligt, E Phielix, T Van De Weijer, J Hansen, ... Diabetes care 39 (12), 2211-2217, 2016 | 132 | 2016 |
| Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first degree relatives of patients with type 2 diabetes M de Ligt, YMH Bruls, J Hansen, MF Habets, B Havekes, ... Molecular metabolism 12, 39-47, 2018 | 63 | 2018 |
| Carnitine supplementation improves metabolic flexibility and skeletal muscle acetylcarnitine formation in volunteers with impaired glucose tolerance: A randomised controlled trial YMH Bruls, M de Ligt, L Lindeboom, E Phielix, B Havekes, G Schaart, ... EBioMedicine 49, 318-330, 2019 | 61 | 2019 |
| No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: A randomized trial M de Ligt, M Bergman, RM Fuentes, H Essers, E Moonen-Kornips, ... The American journal of clinical nutrition 112 (4), 1029-1038, 2020 | 49 | 2020 |
| Effects of the SGLT2 inhibitor dapagliflozin on energy metabolism in patients with type 2 diabetes: a randomized, double-blind crossover trial YJM Op den Kamp, M de Ligt, B Dautzenberg, E Kornips, R Esterline, ... Diabetes care 44 (6), 1334-1343, 2021 | 42 | 2021 |
| Resveratrol supplementation reduces ACE2 expression in human adipose tissue M de Ligt, MKC Hesselink, J Jorgensen, N Hoebers, EE Blaak, ... Adipocyte 10 (1), 408-411, 2021 | 41 | 2021 |
| Elevated plasma branched-chain amino acid levels correlate with type 2 diabetes–related metabolic disturbances F Vanweert, M de Ligt, J Hoeks, MKC Hesselink, P Schrauwen, E Phielix The Journal of Clinical Endocrinology & Metabolism 106 (4), e1827-e1836, 2021 | 39 | 2021 |
| TSH suppression aggravates arterial inflammation — an 18F-FDG PET study in thyroid carcinoma patients E Boswijk, KJC Sanders, EPM Broeders, M de Ligt, GHEJ Vijgen, ... European journal of nuclear medicine and molecular imaging 46, 1428-1438, 2019 | 12 | 2019 |
| Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover … A Veelen, C Andriessen, YO den Kamp, E Erazo-Tapia, M de Ligt, ... Metabolism 140, 155396, 2023 | 11 | 2023 |
| Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism YJM op den Kamp, A Gemmink, M de Ligt, B Dautzenberg, E Kornips, ... Molecular Metabolism 66, 101620, 2022 | 11 | 2022 |
| The angiotensin II type 1 receptor blocker valsartan in the battle against COVID‐19 M de Ligt, MKC Hesselink, J Jorgensen, JWE Jocken, EE Blaak, ... Obesity 29 (9), 1423-1426, 2021 | 8 | 2021 |
| Resveratrol treatment does not reduce arterial inflammation in males at risk of type 2 diabetes: A randomized crossover trial E Boswijk, M de Ligt, MFJ Habets, AMA Mingels, ... Nuklearmedizin-NuclearMedicine 61 (01), 33-41, 2022 | 7 | 2022 |
| Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes VER Parker, D Robertson, E Erazo-Tapia, B Havekes, E Phielix, M de Ligt, ... Nature Metabolism 5 (12), 2086-2093, 2023 | 5 | 2023 |
| Resveratrol‐induced remodelling of myocellular lipid stores: A study in metabolically compromised humans N van Polanen, E Zacharewicz, M de Ligt, S Timmers, E Moonen‐Kornips, ... Physiological Reports 9 (2), e14692, 2021 | 5 | 2021 |
| Effects of the SGLT2 inhibitor dapagliflozin on energy metabolism in patients with type 2 diabetes: a randomized, double-blind crossover trial YJMO den Kamp, M de Ligt, B Dautzenberg, E Moonen-Kornips, ... Improvement of muscle lipid-turnover in insulin resistance and type 2 …, 2022 | 1 | 2022 |
| The effect of SGLT2 inhibitor dapagliflozin on substrate metabolism in humans with prediabetes A Veelen, C Andriessen, Y Op den Kamp, EE Tapia, M de Ligt, ... DIABETOLOGIA 65 (SUPPL 1), S6-S6, 2022 | | 2022 |
| Effect of SGLT2 inhibitor dapagliflozin on skeletal muscle fatty acid metabolism in patients with type 2 diabetes A Gemmink, op den Kamp, YJM, M de Ligt, B Dautzenberg, R Esterline, ... DIABETOLOGIA 65 (SUPPL 1), S5-S5, 2022 | | 2022 |
| Effects of 5 weeks of treatment with dapagliflozin, a SGLT2 inhibitor, on energy metabolism in patients with type 2 diabetes Y Op den Kamp, M de Ligt, BD Dautzenberg, R Esterline, J Hoeks, ... DIABETOLOGIA 63 (SUPPL 1), S115-S115, 2020 | | 2020 |
| Resveratrol as add-on therapy in subjects with well-controlled type 2 diabetes: a randomized controlled trial M de Ligt, S Timmers, E Phielix, T van de Weijer, J Hansen, ... a booster of mitochondria 39, 41, 2018 | | 2018 |
